March 3, 2021
Business News

Ixaka (formerly Rexgenero) Launches as an Integrated Cell and Gene Therapy Company


LONDON–()–Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease, launches today. The Company’s shareholders have funded the business with over £40 million in financing.

Previously Rexgenero Ltd, a UK-based company pioneering the development of cell therapies to treat serious diseases such as cancer and chronic limb-threatening ischaemia (CLTI), the launch of Ixaka follows integration of its nanoparticle gene therapy business in France and a shareholder restructuring.

The new business will continue to develop Ixaka’s proprietary technologies – concentrated multi-cell therapies (MCTs) and targeted nanoparticle (TNP) therapeutics. Ixaka’s…



Click here to view the original article.

Related Posts

You might also like ...

PAN Communications Selected by Healthcare Analytics Leader Definitive Healthcare to Drive Brand Visibility
Notice of Lead Plaintiff Deadline for Shareholders in the Velodyne Lidar, Inc. Class Action Lawsuit
Subscription Business Revenue Grows 437% Over Nearly a Decade as Consumer Buying Preferences Shift from Ownership to Usership